Article
Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study.
Gynecologic oncology - 1 Nov 2023
Chen Fei, Zhang Guo-Nan, Lei Wei, Zhou Shu-Guang, Zhang Ying, Liu Lin, Jia Ying, Xie Rong-Kai, Tian Xiu-Fang, Guo Jie, Yang Yue-Bo, Wang Xue-Feng, Wu Xiao-Mei, Sun Qi-Jian, Zhou Xu, Lin Yang, Zhang You-Zhong, Ma Jun-Qi, Liu Yu-Xiu, Cheng Yi-Fan, Chen Jian-Cui, Qu Quan-Xin, Du Dong-Mei, Wang Gui-Yu, Wang Sheng, Ling Yu-Li, Wu Dai-Fei, Zhang Chun-Fa, Lang Jing-He
Abstract excerpt
BACKGROUND: We previously reported that REBACIN effectively eliminates persistent high-risk human papillomavirus (hrHPV) infection. Here, we conducted a prospective multicenter cohort study to evaluate the safety and effectiveness of REBACIN, taking into account factors such as specific hrHPV subtype and patient's age. METHODS: According to inclusion/exclusion criteria and participant willingness, 3252 patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.